Commercial NEDs for a Cancer Diagnostics company – Diagnostics – Ref.: JVM201022A

Open NED Vacancies
  • Date posted: 24th October 2022
Job Description

ANGLE is an AIM-listed world-leading liquid biopsy company with sample-to-answer solutions. ANGLE’s proven patent-protected platform is a circulating tumor cell (CTC) harvesting technology known as the Parsortix® system, which is the only FDA-cleared platform for harvesting cancer cells for subsequent analysis.

They are seeking to augment their existing board of 5 with 1 or 2 additional members who will bring strong commercial expertise in the markets they are seeking to address; which are pharma services selling Parsortix services to pharma for use in cancer drug trials, corporate partnerships with large diagnostic companies that have downstream analysis assays that can be paired with Parsortix and the sale of products for research and clinical use via direct sales and through distributors.

They are seeking experienced commercially orientated NEDs to join the board that brings expertise in pharma and/or diagnostics, ideally with cancer know-how. A background of previously being a NED for a listed company is not essential. The ability to utilise the experience and professional and personal networks to foster collaborations is important as is good communication skills with a strong voice that is prepared to give objective viewpoints to the Board and offer critical observations of proposals. The role holders must have the flexibility to fit in with the Board culture of a fast-growing ‘smaller Company’.

The roles will require circa 12 days per year with March and September requiring 2 meetings to prepare the half and full-year results.